Peramivir is a transition-state analogue and a potent, specific influenza viral neuraminidase inhibitor with an IC50 of median 0.09 nM. The IC50 for peramivir is markedly lower than that for either zanamivir or oseltamivir. Peramivir increases survival in preclinical influenza models, including mouse and ferret models of highly pathogenic avian influenza H5N1. One day of treatment with peramivir is active, and multiple days of treatment rescues most or all mice with H5N1. Similar data have been obtained in ongoing murine experiments with seasonal influenza A (H1N1)/H274Y. After parenteral administration, peramivir reaches very high plasma concentrations. Peramivir is not metabolized, and is cleared by the means of renal filtration. It has a long half-life, especially in comparison with other neuraminidase inhibitors. Due to the failure of the metabolism of the antivirus compound peramivir, as well as its wide distribution and the excretion in the unchanged form in urine, dosing regimens can be adapted easily for patients with renal impairment and for pediatric populations. Peramivir is originally developed by BioCryst Pharmaceuticals. And peramivir is designed to aim to an antiviral agent. Peramivir has been performed phase III clinical trials for the treatment of influenza.
Another CAS# 229614-55-5
EBioMedicine. 2017 Aug;22:133-142.
C-Reactive Protein Mediating Immunopathological Lesions: A Potential Treatment Option for Severe Influenza A Diseases
Peramivir purchased from AbMole
|Source||EBioMedicine (2017). Figure 6. Peramivir (Abmole Bioscience, USA)|
|Cell Lines||C57 bl/6 mice|
|Incubation Time||48 h|
|Results||In comparison, peramivir or 1,6-bis PC(L) treatment slightly improved the pathological damages. The pathological lesions showed moderate improvement in lungs of peramivir plus 1,6-bis PC treated mice.|
|Body Surface Area (m2)||0.007||0.025||0.15||0.05||0.02||0.5|
|Animal A (mg/kg) = Animal B (mg/kg) multiplied by||Animal B Km|
|Animal A Km|
For example, to modify the dose of Compound A used for a mouse (20 mg/kg) to a dose based on the BSA for a rat, multiply 20 mg/kg by the Km factor for a mouse and then divide by the Km factor for a rat. This calculation results in a rat equivalent dose for Compound A of 10 mg/kg.
|Solubility||10 mM in DMSO|
|Related Anti-infection Products|
|Sapienic acid sodium
Sapienic acid sodium is a fatty acid commonly found on the skin and in mucosa. Sapienic acid sodium is active against Streptococcus sanguinis, Streptococcus mitis and Fusobacterium nucleatum with MBC values of 31.3 μg/mL, 375.0 μg/mL and 93.8 μg/mL, respectively.
Piperaquine phosphate is an orally active bisquinolone antimalarial drug.
Garenoxacin (T-3811ME, BMS-284756) is a novel des-F(6) quinolone that has been shown to be effective in vitro against a wide range of clinically important pathogens, including gram-positive and gram-negative aerobes and anaerobes.
Cefradine is a beta-lactam, first-generation cephalosporin antibiotic with bactericidal activity.
|Bismuth Subcitrate Potassium
Bismuth Subcitrate is an antibiotic used to treat stomach ulcers associated with Helicobacter pylori, a bacterial infection.
Products are for research use only. Not for human use. We do not sell to patients.
© Copyright 2010-2020 AbMole BioScience. All Rights Reserved.